Certain Non-Voting Common Stock of IGM Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2022.
May 27, 2022
Share
Certain Non-Voting Common Stock of IGM Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2022. These Non-Voting Common Stock will be under lockup for 60 days starting from 29-MAR-2022 to 28-MAY-2022.
Details:
directors and officers (the Lock-Up Parties) and the company have agreed that, without the prior written consent of the representatives on behalf of the underwriters, the company and they will not, and will not publicly disclose an intention to, during the period ending 60 days after the date of this prospectus supplement (the restricted period) sell, offer to sell, contract to sell or lend any shares of common stock or any options, warrants or rights to acquire shares of common stock or any securities exchangeable or exercisable for or convertible into shares of common stock, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into shares of common stock (Related Securities), effect any short sale, or establish or increase any put equivalent position (as defined in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any call equivalent position (as defined in Rule 16a-1(b) under the Exchange Act) of any common stock or Related Securities, pledge, hypothecate or grant any security interest in any common stock or Related Securities, in any other way transfer or dispose of any common stock or Related Securities, enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of shares of common stock or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise, announce the offering of any shares of common stock or Related Securities, submit or file any registration statement under the Securities Act in respect of any common stock or Related Securities (other than the common stock offered hereby), effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding common stock or publicly announce any intention to do any of the foregoing.
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Companyâs pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Companyâs development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.